Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. Am Heart J. 2017 Feb; 184:81-87.
View in:
PubMed
subject areas
Aortic Valve Stenosis
Aortic Valve Stenosis
Aspirin
Aspirin
Cardiovascular Diseases
Cardiovascular Diseases
Cause of Death
Cause of Death
Drug Therapy, Combination
Drug Therapy, Combination
Embolism
Embolism
Factor Xa Inhibitors
Factor Xa Inhibitors
Heart Valve Diseases
Heart Valve Diseases
Humans
Humans
Mortality
Mortality
Myocardial Infarction
Myocardial Infarction
Platelet Aggregation Inhibitors
Platelet Aggregation Inhibitors
Postoperative Care
Postoperative Care
Pulmonary Embolism
Pulmonary Embolism
Rivaroxaban
Rivaroxaban
Stroke
Stroke
Thrombosis
Thrombosis
Ticlopidine
Ticlopidine
Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement
Venous Thrombosis
Venous Thrombosis
authors with profiles
Usman Baber